Sumitomo Mitsui Trust Group Inc. Lowers Stock Holdings in Illumina, Inc. $ILMN

Sumitomo Mitsui Trust Group Inc. cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,035,903 shares of the life sciences company’s stock after selling 218,692 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Illumina were worth $127,685,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Elyxium Wealth LLC acquired a new stake in shares of Illumina during the fourth quarter worth $25,000. Board of the Pension Protection Fund acquired a new position in Illumina in the fourth quarter valued at $26,000. Creative Capital Management Investments LLC lifted its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new position in Illumina during the fourth quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Illumina in the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina is being highlighted by market commentary as a biotech and life sciences momentum name, with analysts pointing to stronger earnings trends and sector leadership in healthcare. Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
• Positive Sentiment: Several articles frame ILMN as a strong momentum stock and note that it has outperformed recently, reinforcing bullish trading interest. Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
• Positive Sentiment: Illumina announced new executive appointments, naming Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, which may be viewed as a move to strengthen commercial execution and governance. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
• Positive Sentiment: Illumina also announced it will report second-quarter 2026 results on July 30, keeping attention on upcoming fundamentals and guidance. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
• Neutral Sentiment: Coverage also repeated bullish valuation and “mooning stock” themes, but these were largely commentary pieces rather than new company-specific developments. Illumina Stock Gains 43.7% in 2026: What’s Powering the Rally?
• Negative Sentiment: Short-interest data showed no meaningful bearish positioning change, so it does not currently add fresh downside pressure, though the report itself was unusual and offered little real signal. Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results

Analyst Ratings Changes

ILMN has been the subject of several recent analyst reports. Canaccord Genuity Group lowered their price target on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Evercore reissued an “outperform” rating on shares of Illumina in a research report on Monday. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Guggenheim upped their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Thursday, May 14th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $150.44.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director directly owned 2,830,452 shares in the company, valued at $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Patricia Leckman sold 783 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the sale, the senior vice president directly owned 21,259 shares of the company’s stock, valued at $3,456,500.81. The trade was a 3.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last three months. 2.90% of the stock is owned by company insiders.

Illumina Trading Down 1.8%

NASDAQ:ILMN traded down $3.56 on Friday, hitting $190.20. 1,075,437 shares of the stock were exchanged, compared to its average volume of 1,932,858. The stock has a fifty day moving average of $161.31 and a 200-day moving average of $141.50. The stock has a market cap of $28.78 billion, a PE ratio of 34.58, a PEG ratio of 3.63 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the company posted $0.97 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, equities analysts expect that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.